The firm said it would focus resources on other late-stage programs after a Phase III study showed little survival benefit on first-line bemarituzumab.

Despite another quarter of declining sales for Ibrance, its top-selling oncology drug, revenue for Pfizer's overall oncology ...

The firm missed Wall Street Q4 revenue estimates but assured steady growth as it plans for Keytruda's patent expirations, a ...

The firm is expecting a preliminary data read out from the trial, which is already underway in the US, in the second half of this year.

It will fund validation awards to bring therapies to human trials and innovation awards to those that "push the boundaries" ...

Lilly will license programmable recombinases developed by Seamless to create new gene-editing therapies that could treat ...

Three blood cancer organizations have appealed a NICE draft guidance, which could make the therapy unavailable for mantle ...

EGFR drug ALX2004 and evorpacept, which recently showed activity with Jazz's Ziihera in CD47- and HER2-positive breast cancer.

The agency previously declined to approve the application for UX111, citing issues related to chemistry, manufacturing, and controls (CMC).

The nonprofit biotech recently licensed the gene therapy from Boston Children's Hospital and plans to bring it to low- and middle-income countries.

The company received FDA clearance to launch a Phase I trial of its therapy, which it says can overcome safety and efficacy concerns related to systemic AAV delivery.

Moderna will get $50 million upfront and up to $110 million in near-term development and regulatory milestone payments, among other financial terms.